Home/Pipeline/HTL0014242

HTL0014242

Schizophrenia

Phase 1Completed (Partnered with Neurocrine)

Key Facts

Indication

Schizophrenia

Phase

Phase 1

Status

Completed (Partnered with Neurocrine)

Company

Nxera Pharma

About Nxera Pharma

Nxera Pharma is a Tokyo-based, publicly traded biopharmaceutical company with a mission to deliver transformative medicines by exploiting its proprietary expertise in G protein-coupled receptor (GPCR) structure-based drug design. The company has successfully evolved from a technology licensing model into a robust, pipeline-driven enterprise with 16+ assets, underpinned by its StaR® technology platform and a dual-hub operational model spanning Japan and the UK. Its strategy focuses on advancing internal neuroscience and immuno-oncology candidates while generating significant value through strategic partnerships with major global pharmaceutical companies, positioning it as a key player in the next generation of GPCR-targeted therapeutics.

View full company profile

Therapeutic Areas

Neuroscience Immuno-oncology

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active